Pfizer Pays up to $140 million for Cytos’ Vaccines
01/05/2009
U.S. drugmaker Pfizer has agreed to pay up to $140 million dollars for Cytos Biotechnology Ltd. world-wide exclusive rights to market vaccines, based on Cytos biotech Immunodrug Technology.
Schering-Plough Files European Submission for Fertility Drug
01/05/2009
Schering-Plough Corp. announced that they have sent documentation to the European Medicines Agency for marketing approval for Corifollitropin Alfa, the company's experimental, sustained follicle stimulant (SFS).
PDL BioPharma, Alexion Pharmaceuticals Agree to End Patent Lawsuit for Monoclonal Antibody Soliris
01/05/2009
Biotechnology companies PDL BioPharma Inc. and Alexion Pharmaceuticals Inc., announced that they will jointly end lawsuit over humanized antibody monoclonal Soliris (eculizumab) patents, currently owned by Alexion and PDL's patents known as the “Queen”.
Jeffrey Kindler: Pfizer Open to Buying Competitors
01/05/2009
Pfizer's CEO, Jeffrey Kindler, told the Financial Times that it is willing to buy a competitor in order to grow revenue. Analyst, however, said that merger is just speculation
FDA Approves More New Drugs in 2008 Compared with Last Three Years
01/05/2009
The Food and Drug Administration approved 24 new drugs in 2008, more than in any of the prior three years, the Wall Street Journal reports. The agency approved 18 drugs in 2007, 22 in 2006 and 20 in 2005.
Glenmark Gets FDA Approval For Generic Imuran (GSK)
01/05/2009
U.S. Market: Biovail Withdraws Some Lots of Ultram ER
01/05/2009
- BLOG
- VIDEOS
- NM Extra
Allergan: FDA Approves Latisse to Treat Hypotrichosis
12/30/2008
Allergan Inc. was cleared by the Food and Drug Administration to market Latisse, a solution to treat Hypotrichosis, the first drug to make eyelashes longer, darker and thicker. The main compound is the same a Lumigan, to treat glaucoma since 2001.
Lilly Signs a Licensing Agreement with BioMS to Develop MS Drug Dirucotide
12/30/2008
Eli Lilly signed a licensing agreement with Canadian biotech BioMS, to develop an market the experimental drug Dirucotide, to treat advanced forms of multiple sclerosis. The deal was closed for $497 million dollars.
Ixiaro
Intercell AG Expects FDA Approval for Japanese Encephalitis Vaccine by 2009
12/30/2008
Austrian biotechnology company Intercell AG announced that they are expecting that the Food and Drug Administration will clear by early 2009, marketing approval for its Japanese Encephalitis vaccine, Ixiaro.
